The vaccine allocation, once approved and approved, will be based on an allocation framework released today by WHO, which will respect the principle of fair and equitable access and ensure that no participating economy is lagging behind. The policy of setting priorities for the introduction of vaccines in national economies will be based on the recommendations of the WHO Strategic Advisory Group on Immunization (SAGE), which recently published a values framework that lays the groundwork for the following guidelines for target populations and vaccine use strategies. Gavi and CEPI lead the COVAX pillar – vaccine development, production and distribution as part of the Access to COVID-19 Tools Accelerator (ACT Accelerator) initiative described above. Their roles are delineated: CEPI primarily distributes funds for vaccine research and development and, at the time of writing, eight CEPI-funded vaccines were in clinical trials. [59] Gavi leads efforts to coordinate production and supply through a global vaccine acquisition system, the COVAX Facility. [60] Under the voluntary scheme, self-funded countries must bear higher pre-payment costs, but “they may choose not to receive a vaccine without compromising their ability to obtain their full share of the doses of other applicants, provided that the supply is available.” [63] According to Gavi, discretionary sales contracts would be more attractive to participating countries that have already reserved sufficient doses of a given vaccine through bilateral agreements. [64] Take steps to encourage and facilitate the transfer of technology for a successful Covid 19 vaccine so that it is available where possible. WHO explains that the first vaccines will not be enough to cover 20% of the world`s population, and proposes to allocate a batch of vaccines to each country to cover 3% of its population, which, at least, allows for the vaccination of health professionals on the front line. [48] Additional vaccine batches would then be distributed proportionally until each country received sufficient doses to cover 20 per cent of its population. But the United States – the world`s largest bilateral donor that recently suspended WHO funding – has been remarkably absent from the agreement, which health experts have described as “worrying.” In an August 2020 draft, WHO proposed that Covid 19 vaccines be scarce, but that countries “focus first on reducing mortality and protecting the health system”[40] by identifying target groups based on current scientific and epidemiological data in different environments. prioritizing them within these target groups. In late April 2020, WHO launched the Access to COVID-19 Tools Accelerator (ACT Accelerator), a collaborative platform for governments, major private donors and scientists, which calls on governments and private organizations to fund the “development and equitable distribution” of covid-19 diagnostics, therapeutics and vaccines.

[34] 64 higher-income economies have signed up to COVAX, a comprehensive initiative that brings governments and manufacturers together to ensure that potential COVID 19 vaccines reach those most in need of assistance, whoever they are and wherever they live. These 64 economies include the commitments of 35 economies and the European Commission, which will obtain doses on behalf of 27 EU Member States, as well as Norway and Iceland.

MenĂº